What Eli Lilly investors can learn from the slow launch of a competitor ' s drug

Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for…#elililly #biogen #leqembi #fda #lilly #eisai #medicare #chrisviehbacher #indianapolis #club
Source: Reuters: Health - Category: Consumer Health News Source Type: news